J&J has been betting on Tremfya, as its other blockbuster drug for psoriasis and ulcerative colitis, Stelara, is looking at a patent cliff – which occurs when a company loses its patent protection, allowing cheaper biosimilars to enter the market.
News
US FDA expands J&J’s psoriasis drug for inflammatory bowel disease
October 21, 2024
J&J has been betting on Tremfya, as its other blockbuster drug for psoriasis and ulcerative colitis, Stelara, is looking at a patent cliff – which occurs when a company loses its patent protection, allowing cheaper biosimilars to enter the market.